aycan and Definiens Announce Partnership to Market a Novel Software Solution for the Detection of Lung Tumors
Wuerzberg, Germany / Munich, Germany – November 29, 2010 – aycan, a recognized worldwide leader in medical imaging, and Definiens, the number one Health Image Intelligence™ company, today announced their partnership and first joint project to quantify and analyze lung tumors.
Under the partnership, Definiens has combined its Definiens LungExpert™ with aycan’s OsiriX PRO – a Class II FDA-cleared and Class IIb CE-labeled medical device – to create a workstation that quantifies lung tumors according to RECIST and WHO guidelines and also by their volume. This new integrated solution enables efficient analysis of lesions, including automated quantification of lung tumors. Definiens LungExpert™, which helps radiologists monitor tumor therapy progress, is the company’s second image analysis application for the efficient treatment of cancer.
“The intuitive user interface and plugin capabilities of OsiriX PRO enabled us to seamlessly pair it with Definiens LungExpert, resulting in an extremely fast and easy-to-use solution. aycan's professional support made it easy for us to utilize the popular OsiriX platform,” said Oliver Lehner, Vice President, Clinical Solutions Business at Definiens. “Definiens LungExpert™ allows new levels of automation and efficiency in lung tumor analysis. Adding this software to OsiriX PRO is another example of how aycan responds to the trend toward more quantitative and standardized diagnostics. This is in line with QIBA – Goals (Quantitative Imaging Biomarkers Alliance) to increase the utility and value of imaging.”
“We are excited about this cooperation,” added Stephan Popp, CEO of aycan. “Definiens is one of the leading innovators in the area of image analysis and quantification. Its software combined with our Apple-based post processing OsiriX PRO platform will allow us to bring many other innovative solutions to the market.”
The new workstation is expected to be available in early 2011 from aycan. A first version will be showcased by Definiens at RSNA Annual Meeting 2010 within the Quantitative Imaging Reading Room.
About aycan aycan is a leading provider of cost effective turnkey solutions and services for the medical imaging market. aycan was founded in Germany in 1995 by radiologists and German engineers with the introduction of aycan xray-print, today's market leading DICOM paper print solution. Built on this success and core competency in DICOM, aycan has expanded its offering with other innovative solutions for medical imaging, such as PACS, DICOM viewing and system integration, OsIrX PRO, and aycan store. aycan works with other industry innovators such as Xerox and Apple, whose quality products are part of aycan solutions. aycan supports customers worldwide with European headquarters in Wuerzburg Germany, and U.S. headquarters in Rochester, New York. The company is privately held. Learn more at www.aycan.com
About Definiens Definiens is the number one Health Image Intelligence™ company for analyzing and interpreting images on every scale – from microscopic cell structures to full body scans. The Definiens Cognition Network Technology®, developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Healthcare markets. It is modeled on the powerful human cognitive perception processes to extract intelligence from images.
Definiens supports biopharmaceutical companies, clinical service organizations, and academic research institutions by automating image analysis - from drug discovery to diagnostics. The company’s image analysis software enables the interpretation of vast numbers of digital images accurately and consistently. Definiens software for digital pathology and radiology images reveals biologically relevant insights for the advancement of translational research and personalized medicine. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better medical decisions. The company is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.